Skip to main content
. 2017 Jun 27;8(39):65339–65358. doi: 10.18632/oncotarget.18689

Figure 6. In vivo efficacy and bioavailability of SSTR2pep-DIM-NPs.

Figure 6

(A) Representative images of untreated (large) and treated (small) rat brain tumors, (B) H&E staining of their sections and (C) comparison of survivability between the two groups (n=6 in each group). Data is represented as mean ± SEM and *indicates P<0.001. (D) Figure represents overall survival curve for rats with orthotopic brain tumor. At the 31st day after treatment maximum survival rate is 73.33% for SSTR2pep-DIM-NP treated group, whereas for untreated, native DIM treated and nonspecific peptide treated groups the percentages are 0%, 0% and 33.33% respectively (n=6 in each group). (E) Graphs showing the tumor volume as a function of time with and without SSTR2pep-DIM-NP treatment. (F) Graphical representation shows time-course of plasma concentrations over 48 hr following intravenous administration of 2.5 mg/kg native DIM, DIM-NPs and SSTR2pep-DIM-NPs to the adult SD rats (n=6 in each group). (G) Table represents the parameters of bioavailability studied for the nanoformulations.